SUBSCRIBE
SUBSCRIBE
News   Drug Development

Actelion Ltd., GlaxoSmithKline Stop Development of Insomnia Medicine on Safety Concern

January 28, 2011 | 
1 min read
Bloomberg -- Actelion Ltd. and partner GlaxoSmithKline Plc stopped late-stage development of the experimental almorexant insomnia pill because of concern that patients wouldn’t be able to tolerate the medicine.
Clinical research Phase 3
GlaxoSmithKline
MORE ON THIS TOPIC
Insights
ALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs
February 26, 2026
 · 
1 min read
 · 
Jennifer Smith-Parker
Close up shot of the dart arrow hit on bulleyes of dartboard to represent that the business reached the target with dark tone picture style. Target and goal as concept.
Diabetes
Lilly Tops Novo in Weight Loss Again, This Time on the Oral Front
February 26, 2026
 · 
2 min read
 · 
Annalee Armstrong
Working man icon pushing the load on the line. Hard work, labor, effort and determination concept.
HIV
Gilead, Merck Clear Path to Market for Daily HIV Pills With New Late-Stage Data
February 26, 2026
 · 
2 min read
 · 
Tristan Manalac
Alarm clock with pause sign, take a break, menopause concept, hormone replacement therapy
Regulatory
Patient Death Forces Partial Freeze on MacroGenics’ Gynecologic Cancer Study
February 25, 2026
 · 
2 min read
 · 
Tristan Manalac